Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suddhasatta Acharyya

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
The American Journal of Drug and Alcohol Abuse|May 27, 2003
Assessing sex differences on treatment effectiveness from the drug abuse treatment outcome study (DATOS)Suddhasatta Acharyya, Heping Zhang
Contemporary Clinical Trials|December 13, 2016
Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: Meta-analyses of published studiesMadan G Kundu, Suddhasatta Acharyya
Contemporary Clinical Trials|July 19, 2017
Corrigendum to "Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: Meta-analyses of published studies" [Contemp. Clin. Trials 53 (2017) 20-28]Madan G Kundu, Suddhasatta Acharyya
Journal of Developmental and Behavioral Pediatrics : JDBP|October 28, 2003
Developmental trajectories of cocaine-and-other-drug-exposed and non-cocaine-exposed childrenLinda C Mayes, Domenic Cicchetti, Suddhasatta Acharyya, et al.
Biological Psychiatry|January 22, 2002
The spectrum of social phobia in the Zurich cohort study of young adultsKathleen Ries Merikangas, Shelli Avenevoli, Suddhasatta Acharyya, et al.
Archives of General Psychiatry|October 15, 2003
Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort StudyKathleen Ries Merikangas, Heping Zhang, Shelli Avenevoli, et al.
Expert Review of Hematology|September 9, 2017
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agentPaul Richardson, Anuja Roy, Suddhasatta Acharyya, et al.
Journal of Nutrition Education and Behavior|July 4, 2007
Assessing fat-related dietary behaviors among black women: reliability and validity of a new Food Habits QuestionnairePatricia Markham Risica, Gary Burkholder, Kim M Gans, et al.
British Journal of Haematology|May 19, 2018
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trialPaul G Richardson, Robert L Schlossman, Anuja N Roy, et al.
Radiology|April 20, 2011
Use of BI-RADS 3-probably benign category in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening TrialJanet K Baum, Lucy G Hanna, Suddhasatta Acharyya, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
The American Journal of Drug and Alcohol Abuse|May 27, 2003
Assessing sex differences on treatment effectiveness from the drug abuse treatment outcome study (DATOS)Suddhasatta Acharyya, Heping Zhang
Contemporary Clinical Trials|December 13, 2016
Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: Meta-analyses of published studiesMadan G Kundu, Suddhasatta Acharyya
Contemporary Clinical Trials|July 19, 2017
Corrigendum to "Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: Meta-analyses of published studies" [Contemp. Clin. Trials 53 (2017) 20-28]Madan G Kundu, Suddhasatta Acharyya
Journal of Developmental and Behavioral Pediatrics : JDBP|October 28, 2003
Developmental trajectories of cocaine-and-other-drug-exposed and non-cocaine-exposed childrenLinda C Mayes, Domenic Cicchetti, Suddhasatta Acharyya, et al.
Biological Psychiatry|January 22, 2002
The spectrum of social phobia in the Zurich cohort study of young adultsKathleen Ries Merikangas, Shelli Avenevoli, Suddhasatta Acharyya, et al.
Archives of General Psychiatry|October 15, 2003
Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort StudyKathleen Ries Merikangas, Heping Zhang, Shelli Avenevoli, et al.
Expert Review of Hematology|September 9, 2017
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agentPaul Richardson, Anuja Roy, Suddhasatta Acharyya, et al.
Journal of Nutrition Education and Behavior|July 4, 2007
Assessing fat-related dietary behaviors among black women: reliability and validity of a new Food Habits QuestionnairePatricia Markham Risica, Gary Burkholder, Kim M Gans, et al.
British Journal of Haematology|May 19, 2018
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trialPaul G Richardson, Robert L Schlossman, Anuja N Roy, et al.
Radiology|April 20, 2011
Use of BI-RADS 3-probably benign category in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening TrialJanet K Baum, Lucy G Hanna, Suddhasatta Acharyya, et al.
Pageof 3